BeiGene and SpringWorks enter trial collaboration for solid tumors
BeiGene Ltd. and SpringWorks Therapeutics partnered to evaluate the combination of BeiGene’s lifirafenib (BGB283) with SpringWorks’ PD0325901 as a new treatment regimen for solid tumors.
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.